Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours By Ogkologos - February 17, 2026 302 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DELII study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Few People with Cancer Undergo Testing for Inherited Gene Mutations August 1, 2023 Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... February 3, 2025 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... June 7, 2019 A new year of expanding research horizons January 21, 2022 Load more HOT NEWS Recognising the essential role of clinical research nurses Higher Risk of Heart Failure Seen in Some Cancers Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... This Saturday: National Prescription Drug Take-Back Day
